| Region: | |
| Category: |
(14 reports matching your criteria)
|
TreatmentTrends®: Advanced/Metastatic Breast Cancer (US) 2012
11/30/2012 | published by: Decision Resources
... provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players. Please ...
|
read more...
|
$15,000.00
|
|
ChartTrends®: Lupus (US) 2012
11/27/2012 | published by: Decision Resources
... syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, ...
|
read more...
|
$15,000.00
|
|
ChartTrends®: Bone and Mineral Metabolism in CKD-ND (US) 2012
10/30/2012 | published by: Decision Resources
... (CKD) patient records. BioTrends has been covering the US Dialysis and CKD markets since 2004. This will be the seventh wave of the ChartTrends report. ChartTrends® are syndicated reports designed to compare what physicians self-report ...
|
read more...
|
$15,000.00
|
|
Early Toxicology: Markets and Approaches
9/12/2012 | published by: Kalorama Information
... Toxicity determinations are an integral part of all aspects of drug discovery & development. This report, Early Toxicology Markets and Approaches , focuses on markets for early toxicology testing services. The objective of this report ...
|
read more...
|
$3,995.00
|
|
ChartTrends®: Rheumatoid Arthritis (US) 2012
9/11/2012 | published by: Decision Resources
... what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, concomitant medications, and a host ...
|
read more...
|
$15,000.00
|
|
PatientTrends®: Rheumatoid Arthritis (US) 2012
8/17/2012 | published by: Decision Resources
... satisfaction with their physician and their thera-peutic regimen. This report will also examine how patients seek out information about their disease and what product attributes would encour-age patients to seek a switch in therapies, particularly ...
|
read more...
|
$10,000.00
|
|
PAREXEL Biopharmaceutical R&D Statistical Sourcebook 2012/2013
7/1/2012 | published by: Barnett Educational Services
... the latest market intelligence on every aspect of biopharmaceutical development – from product discovery, to R&D performance and productivity, to time-to-market trends. With key analysis and contributions from leading consultancies and experts, the Sourcebook provides ...
|
read more...
|
$425.00
|
|
LaunchTrends®: Victrelis and Incivek (Hepatitis C Virus) (Wave 4) (US) 2012
5/30/2012 | published by: Decision Resources
... months immediately following the May 2011 launch. Reports are based on data collected at one month, three months, six months, and one year following the launch of these products. These report series track the trial, ...
|
read more...
|
$15,000.00
|
|
Dramatic Changes in the Malignant Melanoma Landscape: How Will U.S. Payers and Prescribers Limit or Promote Market Access for Recently Launched and Emerging Brands?
3/22/2012 | published by: Decision Resources
... of unresectable patients is extremely poor, as exemplified by a five-year survival rate of approximately 15%. Until very recently therapeutic options for malignant melanoma have be severely limited and remain unchanged. With over three decades ...
|
read more...
|
$15,000.00
|
|
Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US
12/31/2011 | published by: GBI Research
... Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US” which provides key data, information and analysis of the major trends and issues affecting the clinical trial market in Poland. The ...
|
read more...
|
$3,500.00
|
|
Drugs in Development: From Pipeline to Market 2011
7/1/2011 | published by: PharmaLive Special Reports
... period June 2010 through May 2011. Drugs are organized by their approved or development status. Each section provides: Commercial name or product code Chemical or substance composition Approved or intended indication Developer with company Website
|
read more...
|
$485.00
|
|
Phase IV Clinical Trials
7/1/2011 | published by: Cutting Edge Information
... IV studies are a growing necessity — but they often remain deprioritized and under-resourced as teams struggle to marshal needed support for both strategy and execution. Use this study to reinforce Phase IV research and ...
|
read more...
|
$7,695.00
|
|
Emerging Market for Clinical Trials in Argentina - Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug Development
7/1/2011 | published by: GBI Research
... in Argentina - Major Cost Advantages over the US in Conducting Clinical Trials Will Encourage Drug Development” that provides key data, information and analysis of the major trends and issues affecting the clinical trial market ...
|
read more...
|
$3,500.00
|
|
Offshoring Clinical Trials (The Market for Clinical Trials in India, China, Mexico, Brazil, Russia and Israel.)
11/1/2007 | published by: Kalorama Information
... problems. This provides an opportunity for BRIC countries and other developing regions to grab a piece of the clinical trial market. Countries such as India and China have a vast population who are interested in ...
|
read more...
|
$1,500.00
|